Equitable Trust Co. Takes $676,000 Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Equitable Trust Co. bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the fourth quarter, Holdings Channel reports. The fund bought 1,635 shares of the company’s stock, valued at approximately $676,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in IDEXX Laboratories by 400.0% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 500 shares of the company’s stock valued at $253,000 after purchasing an additional 400 shares in the last quarter. Carnegie Investment Counsel purchased a new position in IDEXX Laboratories in the 3rd quarter valued at $205,000. Procyon Advisors LLC lifted its holdings in IDEXX Laboratories by 2.2% in the 3rd quarter. Procyon Advisors LLC now owns 1,544 shares of the company’s stock valued at $780,000 after purchasing an additional 33 shares in the last quarter. Creative Planning lifted its holdings in IDEXX Laboratories by 2.6% in the 3rd quarter. Creative Planning now owns 24,436 shares of the company’s stock valued at $12,346,000 after purchasing an additional 614 shares in the last quarter. Finally, RDA Financial Network lifted its holdings in IDEXX Laboratories by 25.2% in the 3rd quarter. RDA Financial Network now owns 1,771 shares of the company’s stock valued at $895,000 after purchasing an additional 357 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of research reports. Leerink Partners initiated coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective on the stock. Morgan Stanley reduced their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Bank of America lifted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Finally, StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Stock Up 1.1 %

Shares of NASDAQ:IDXX opened at $464.91 on Tuesday. The business has a 50-day moving average price of $428.35 and a 200 day moving average price of $453.32. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $38.07 billion, a price-to-earnings ratio of 43.57, a PEG ratio of 3.47 and a beta of 1.37. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now directly owns 905 shares of the company’s stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.